Tamir Biotechnology, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1981-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://tamirbio.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Phase 1
Completed
- Conditions
- Condylomata AcuminataPapillomavirus InfectionsSexually Transmitted Diseases
- Interventions
- Drug: Vehicle
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Tamir Biotechnology, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02535104
- Locations
- 🇧🇴
IDH, Cochabamba, Bolivia
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2010-08-18
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Tamir Biotechnology, Inc.
- Registration Number
- NCT01184287
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸Van Andel Research Institute, Grand Rapids, Michigan, United States
🇺🇸Sletten Cancer Specialists, Great Falls, Montana, United States
News
No news found